Now showing items 1-14 of 14

    • Contribution of systemic T cell immunity to clinical efficacy of anti-PD-L1/PD-1 immunotherapies in lung cancer 

      Zuazo Ibarra, Miren Upna Orcid (2020)   Tesis doctoral / Doktoretza tesia  OpenAccess
      Un alto porcentaje de pacientes con cáncer de pulmón resistentes a terapias convencionales son refractarios a la inmunoterapia con anticuerpos bloqueadores de la interacción PD-L1/PD-1. En la presente tesis doctoral se ha ...
    • Early detection of hyperprogressive disease in non-small cell lung cancer by monitoring of systemic T cell dynamics 

      Arasanz Esteban, Hugo; Zuazo Ibarra, Miren Upna Orcid; Bocanegra Gondan, Ana Isabel; Gato Cañas, María; Martínez Aguillo, Maite; Morilla Ruiz, Idoia (MDPI, 2020)   Artículo / Artikulua  OpenAccess
      Hyperprogressive disease (HPD) is an adverse outcome of immunotherapy consisting of an acceleration of tumor growth associated with prompt clinical deterioration. The definitions based on radiological evaluation present ...
    • Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy 

      Zuazo Ibarra, Miren Upna Orcid; Gato Cañas, María; Llorente, Noelia; Ibáñez-Vea, María Upna Orcid; Arasanz Esteban, Hugo; Kochan, Grazyna; Escors, David (AME Publishing, 2017)   Artículo / Artikulua  OpenAccess
      Programmed cell death-1 (PD1) has become a significant target for cancer immunotherapy. PD1 and its receptor programmed cell death 1 ligand 1 (PDL1) are key regulatory physiological immune checkpoints that maintain ...
    • The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity 

      Edwards, Carolyn J.; Sette, Angelica; Cox, Carl; Di Fiore, Barabara; Wyre, Chris; Sydoruk, Daniela; Yadin, David; Hayes, Philip; Stelter, Szymon; Bartlett, Phillip D.; Zuazo Ibarra, Miren Upna Orcid; García-Granda, María Jesús; Benedetti, Giovanni; Fiaska, Stratonik; Birkett, Neil R.; Teng, Yumin; Enever, Carrie; Arasanz Esteban, Hugo; Bocanegra Gondan, Ana Isabel; Chocarro, Luisa Upna Orcid; Fernández, Gonzalo; Vera, Ruth; Archer, Bethan; Osuch, Isabelle; Lewandowska, Martyna; Surani, Yasmin M.; Kochan, Grazyna; Escors Murugarren, David; Legg, James; Pierce, Andrew J. (Springer Nature, 2021)   Artículo / Artikulua  OpenAccess
      Background: improving cancer immunotherapy long-term clinical benefit is a major priority. It has become apparent that multiple axes of immune suppression restrain the capacity of T cells to provide anti-tumour activity ...
    • PD-L1 expression in systemic immune cell populations as a potential predictive biomarker of responses to PD-L1/PD-1 blockade therapy in lung cancer 

      Bocanegra, Ana; Fernandez-Hinojal, Gonzalo; Zuazo Ibarra, Miren Upna Orcid; Arasanz Esteban, Hugo; Garcia-Granda, María Jesús; Hernandez, Carlos; Ibáñez-Vea, María Upna Orcid; Hernandez-Marin, Berta; Martinez-Aguillo, Maite; Lecumberri, María José; Fernández de Lascoiti, Ángela; Teijeira, Lucía; Morilla, Idoia; Vera, Ruth; Escors Murugarren, David; Kochan, Grazyna (MDPI, 2019)   Artículo / Artikulua  OpenAccess
      PD-L1 tumor expression is a widely used biomarker for patient stratification in PD-L1/PD-1 blockade anticancer therapies, particularly for lung cancer. However, the reliability of this marker is still under debate. Moreover, ...
    • PD-L1 in systemic immunity: unraveling its contribution to PD-1/PD-L1 blockade immunotherapy 

      Bocanegra Gondan, Ana Isabel; Blanco, Ester; Fernández Hinojal, Gonzalo; Chocarro, Luisa Upna Orcid; Zuazo Ibarra, Miren Upna Orcid (MDPI, 2020)   Artículo / Artikulua  OpenAccess
      The use of monoclonal antibodies targeting PD-1/PD-L1 axis completely changed anticancer treatment strategies. However, despite the significant improvement in overall survival and progression-free survival of patients ...
    • PD1 signal transduction pathways in T cells 

      Arasanz Esteban, Hugo; Gato Cañas, María; Zuazo Ibarra, Miren Upna Orcid; Ibáñez-Vea, María Upna Orcid; Breckpot, Karine; Kochan, Grazyna; Escors, David (Impact Journals, 2017)   Artículo / Artikulua  OpenAccess
      The use of immune checkpoint inhibitors for the treatment of cancer is revolutionizing oncology. Amongst these therapeutic agents, antibodies that block PD-L1/PD1 interactions between cancer cells and T cells are demonstrating ...
    • PDL1 signals through conserved sequence motifs to overcome interferon-mediated cytotoxicity 

      Gato Cañas, María; Zuazo Ibarra, Miren Upna Orcid; Arasanz Esteban, Hugo; Ibáñez-Vea, María Upna Orcid; Lorenzo, Laura; Fernandez-Hinojal, Gonzalo; Vera García, Ruth; Smerdou, Cristian; Martisova, Eva; Arozarena, Imanol; Wellbrock, Claudia; Llopiz, Diana; Ruiz, Marta; Sarobe, Pablo; Breckpot, Karine; Kochan, Grazyna; Escors, David (Elsevier, 2017)   Artículo / Artikulua  OpenAccess
      PDL1 blockade produces remarkable clinical responses, thought to occur by T cell reactivation through prevention of PDL1-PD1 T cell inhibitory interactions. Here, we find that PDL1 cell-intrinsic signaling protects cancer ...
    • Profound reprogramming towards stemness in pancreatic cancer cells as adaptation to AKT inhibition 

      Arasanz Esteban, Hugo; Hernández, Carlos; Bocanegra Gondan, Ana Isabel; Chocarro, Luisa Upna Orcid; Zuazo Ibarra, Miren Upna Orcid (MDPI, 2020)   Artículo / Artikulua  OpenAccess
      Cancer cells acquire resistance to cytotoxic therapies targeting major survival pathways by adapting their metabolism. The AKT pathway is a major regulator of human pancreatic adenocarcinoma progression and a key pharmacological ...
    • A proteomic atlas of lineage and cancer-polarized expression modules in myeloid cells modeling immunosuppressive tumor-infiltrating subsets 

      Blanco, Ester; Ibáñez-Vea, María Upna Orcid; Hernández, Carlos; Drici, Lylia; Martínez de Morentin Iribarren, Xabier; Gato Cañas, María; Ausín, Karina; Bocanegra Gondan, Ana Isabel; Zuazo Ibarra, Miren Upna Orcid; Chocarro, Luisa Upna Orcid; Arasanz Esteban, Hugo; Fernández Hinojal, Gonzalo; Fernández Irigoyen, Joaquín Upna Orcid; Smerdou, Cristian; Garnica, Maider; Echaide, Miriam; Fernández Rubio, Leticia; Morente Sancho, Pilar; Ramos-Castellanos, Pablo; Llopiz, Diana; Santamaría, Enrique; Larsen, Martin R.; Escors Murugarren, David; Kochan, Grazyna (MDPI, 2021)   Artículo / Artikulua  OpenAccess
      Monocytic and granulocytic myeloid-derived suppressor cells together with tumor-infiltrating macrophages constitute the main tumor-infiltrating immunosuppressive myeloid populations. Due to the phenotypic resemblance to ...
    • Systemic blood immune cell populations as biomarkers for the outcome of immune checkpoint inhibitor therapies 

      Hernández, Carlos; Arasanz Esteban, Hugo; Chocarro, Luisa Upna Orcid; Bocanegra Gondan, Ana Isabel; Zuazo Ibarra, Miren Upna Orcid (MDPI, 2020)   Artículo / Artikulua  OpenAccess
      The development of cancer immunotherapy in the last decade has followed a vertiginous rhythm. Nowadays, immune checkpoint inhibitors (ICI) which include anti-CTLA4, anti-PD-1 and anti-PD-L1 antibodies are in clinical use ...
    • Systemic CD4 immunity: a powerful clinical biomarker for PD-L1/PD-1 immunotherapy 

      Zuazo Ibarra, Miren Upna Orcid; Arasanz Esteban, Hugo; Bocanegra Gondan, Ana Isabel; Chocarro, Luisa Upna Orcid; Vera García, Ruth (EMBO Press, 2020)   Artículo / Artikulua  OpenAccess
      The search for non-invasive systemic biomarkers of response to PD-L1/PD-1 blockade immunotherapy is currently a priority in oncoimmunology. In contrast to classical tumor biomarkers, the identification of clinically useful ...
    • TNF-α-secreting tumor-infiltrated monocytes play a pivotal role during anti-PD-L1 immunotherapy 

      Zuazo Ibarra, Miren Upna Orcid; Ridder, Kirsten de; Locy, Hanne; Piccioni, Elisa; Awad, Robin Maximilian; Verhulst, Stefaan; Van Bulck, Mathias; Vlaeminck, Yannick de; Lecoq, Quentin; Reijimen, Eva; Mey, Wout de; Beck, Lien de; Ertveldt, Thomas; Pintelon, Isabel; Timmermans, Jean-Pierre; Escors Murugarren, David; Keyaerts, Marleen; Breckpot, Karine; Goyvaerts, Cleo (Frontiers Media, 2022)   Artículo / Artikulua  OpenAccess
      Immune checkpoint blockade (ICB) of the PD-1 pathway revolutionized the survival forecast for advanced non-small cell lung cancer (NSCLC). Yet, the majority of PD-L1+ NSCLC patients are refractory to anti-PD-L1 therapy. ...
    • Understanding LAG-3 Signaling 

      Chocarro, Luisa Upna Orcid; Blanco, Ester; Zuazo Ibarra, Miren Upna Orcid; Arasanz Esteban, Hugo; Bocanegra Gondan, Ana Isabel; Fernández Rubio, Leticia; Morente Sancho, Pilar; Fernández Hinojal, Gonzalo; Echaide, Miriam; Garnica, Maider; Ramos, Pablo; Vera García, Ruth; Kochan, Grazyna; Escors Murugarren, David (MDPI, 2021)   Artículo / Artikulua  OpenAccess
      Lymphocyte activation gene 3 (LAG-3) is a cell surface inhibitory receptor with multiple biological activities over T cell activation and effector functions. LAG-3 plays a regulatory role in immunity and emerged some time ...